Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Fig. 1

Cumulative proportion of patients changing second-line therapy over time according to treatment group. Frequency is shown as proportion of 1. DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea. *Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us